FL-WAX
22.11.2021 14:51:07 CET | Business Wire | Press release
Metasaurs , one of the fastest-growing NFT communities in the world, and WAX ($3.5B market cap), the most utilized blockchain in the world for games, processing three-quarters of all game-related transactions daily, announced a ground-breaking partnership to bring new world-class P2E (play-to-earn) games to the WAX ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211122006228/en/
The creators of Metasaurs and founders of WAX will be co-founding a new NFT gaming studio, MetaGames to develop new game projects including the official Metasaurs Game and the launch of the RAWR token to be released in Q1 2022.
Since its inception in 2017, WAX has been coined “The King of NFTs,” but it’s so much more. WAX’s vIRL® technology is leading the future of digital commerce and it is the #1 blockchain by transaction volume in the world. It currently has more than 8M monthly users and is growing 400k+ users per month.
The WAX gaming-optimized blockchain processes 15 million transactions per day and is the #2 layer-1 blockchain behind only Ethereum in daily and 30 day NFT sales volume. Alien Worlds, one of the most popular games in the world, is built on the WAX blockchain, and independently boasts a $2.3B market cap for its own in-game economy.
"The foundation of WAX was built on gaming,” said William E. Quigley, co-founder of WAX, “and the official Metasaurs Game is the perfect use case for a play-to-earn gaming franchise created on WAX, taking advantage of our high volume transaction capacity, unique fee structure of no minting and gifting transaction fees, and energy efficient and low carbon footprint.”
Metasaurs are Dinosaur-Bored Ape hybrids of the popular Bored Ape Yacht Club NFT. The extended storyline, based on Dr. DMT, creating the Metasaurs, unlocks endless creative potential with regard to future games, avatars, and other multi-media on the WAX platform and across the emerging metaverse.
"It is our mission to create fun games which will share their economies with the lifeblood of the community—the players—rather than siphoning all value only to the publishers,” said Merlin Kauffman, creator of Metasaurs. ”Blockchain technology is best suited for this use-case, and we are excited to partner with WAX to create differentiated gaming experiences for the mass market."
“Merlin is a grassroots thought-leader in the NFT space,” said Quigley. “His track record building one of the most passionate fastest-growing NFT communities combined with our deep knowledge of NFT gaming economies put us in a privileged position to co-create the official Metasaurs Game. Our gaming studio, MetaGames, has all the right ingredients to create a series of successful play-to-earn gaming franchises.”
Quigley continued, “As we spend an increasing amount of time virtually than ever before, NFTs pave a way for users to have a stake in these new applications and digital worlds. WAX is at the forefront of this gaming evolution in the way we live online, building tools in a way that benefits everyone involved.”
About Metasaurs
The genesis Metasaurs collection is 9,999 NFTs created by Dr. DMT in The Lab from 300+ hand-drawn traits, each Metasaur consists of between 4-7 combined traits, of various rarities. Dr. DMT is authentic BAYC Ape #4588, and he is constantly developing new formulas to expand the Metasaurs experiment. The possibilities are endless, like the infinite lifespans of these Metasaurs on the blockchain .
About WAX - The King of NFTs
The Worldwide Asset eXchange ™ (WAX), aka the King of NFTs, is the world’s #1 blockchain, as measured by number of users and transactions, according to Dappradar.com. WAX’s mission is to bring NFTs to the mass market in the safest, most secure, environmentally friendly, and easy-to-use marketplace in the world. WAX is also the leading entertainment NFT network — in 2018, WAX introduced vIRLs® , giving consumer product companies the ability to directly link NFTs to physical consumer products.
About MetaGames Studio
Creators of world-class games, we are building the future of play-to-earn gaming experiences on the WAX blockchain. Co-founded by William Quigley, Merlin Kauffman, and Ben Bindell in 202, with initial studio development of the official Metasaurs Game and RAWR token to be released in Q1 2022. MetaGames ’ mission is to build branded social gaming communities that share their economies with the players, rather than siphoning all of the value only to the game publishers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006228/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom